Armistice Capital Increases Position in Ekso Bionics Holdings to 4.99% Stake

Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A on May 15, 2026, disclosing a 4.99% ownership stake in Ekso Bionics Holdings, Inc. (EKSO). The filing indicates that the reporting persons beneficially own 187,151 shares of common stock as of the event date of March 31, 2026. This position is held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. The current filing represents an increase in holdings compared to the previous reported position of zero shares. Despite the 4.99% stake, the reporting persons have certified that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over the reported shares. The filing was submitted as Amendment No. 4, reflecting the updated ownership status below the 5% threshold typically requiring more frequent reporting for active investors.